Aquestive Therapeutics Announces Departure of Chief Fiscal Officer and Appointment of …

WARREN, N.J., Dec. 16, 2020 (World NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical organization focused on developing and commercializing differentiated products that address patients’ unmet wants and fix therapeutic difficulties, currently announced that John Maxwell, Senior Vice President, Main Monetary Officer (CFO) of the Company, has supplied his intent to resign his positions with the Business to pursue other interests. Latest ideas get in touch with for Mr. Maxwell to continue to provide as CFO of the Enterprise right up until his departure, which now is predicted at calendar year finish. Mr. Ernie Toth, a seasoned monetary government most not long ago with EHE Wellness as Main Money Officer, will think the part of CFO on an interim basis on Mr. Maxwell’s departure.

“We have made meaningful progress in our business considering that John joined the Business in January 2017,” stated Keith J. Kendall, President and Chief Government Officer of Aquestive. “John has been a valuable section of the continued growth of the Business. We thank him for his contributions, in particular in shepherding our attempts to come to be a community enterprise and close various essential funds markets transactions. The administration workforce and board of administrators of Aquestive joins me in wishing him effectively in his foreseeable future business enterprise pursuits. We foresee effecting a quite sleek transition over the upcoming few weeks and are pleased to welcome Mr. Toth as the new interim CFO to our team,” concluded Mr. Kendall.

“I have savored my time with Aquestive Therapeutics,” claimed Mr. Maxwell. “Upon arrival, my rapid goal was to aid evolve the capitalization of the Organization. Aquestive was in the midst of its transformation into a professional proprietary pharmaceutical firm. Getting achieved this vital goal, I think the Organization is properly positioned for long term progress and I believe in the power of the Aquestive company. I desire the staff all the ideal for its ongoing achievements.”

The Corporation also described that Mr. Maxwell’s departure is not relevant to the Company’s operations, fiscal reporting or controls.

2020 Outlook

The Business also introduced that there is no modify to its comprehensive 12 months 2020 economic outlook.

About Aquestive Therapeutics
Aquestive Therapeutics is a pharmaceutical business that applies revolutionary technological innovation to fix therapeutic issues and increase medications for sufferers. The Firm has commercialized a person internally-made proprietary merchandise to date, Sympazan, has a commercial proprietary product or service pipeline focused on the treatment of illnesses of the central nervous technique, or CNS, and other unmet requires, and is producing orally administered complicated molecules to present alternate options to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical businesses to bring new molecules to current market employing proprietary, ideal-in-class systems, like PharmFilm®, and has established capabilities for drug development and commercialization.

Forward-Seeking Assertion
This push launch contains forward-on the lookout statements within the which means of the Non-public Securities Litigation Reform Act of 1995. Phrases this kind of as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the unfavorable of all those conditions, and similar expressions, are supposed to discover ahead-hunting statements. These ahead-hunting statements involve, but are not restricted to, statements relating to therapeutic advantages and designs and objectives for regulatory approvals of AQST-108 and Libervant capability to address the fears recognized in the FDA’s Comprehensive Response Letter dated September 25, 2020 relating to the New Drug Software for Libervant and receive Fda acceptance of Libervant for U.S. market accessibility means to receive Fda acceptance and progress AQST-108, Libervant and our other solution candidates to the current market about our advancement and potential monetary and functioning results and economical position regulatory acceptance and pathway medical demo timing and programs our and our competitors’ orphan drug approval and ensuing drug exclusivity for our items or goods of our opponents short-term and prolonged-phrase liquidity and hard cash prerequisites, cash funding and hard cash melt away business enterprise strategies, market place chances, and other statements that are not historic points. These forward-on the lookout statements are also subject to the unsure impression of the COVID-19 global pandemic on our business enterprise which include with regard to our medical trials which include site initiation, patient enrollment and timing and adequacy of medical trials on regulatory submissions and regulatory opinions and approvals of our solution candidates pharmaceutical component and other uncooked resources supply chain, manufacture, and distribution sale of and demand for our items our liquidity and availability of capital sources consumer demand from customers for our goods and services customers’ skill to fork out for items and providers and ongoing availability of an suitable labor pressure and experienced professionals. Given these uncertainties, the Corporation is not able to deliver assurance that functions can be taken care of as planned prior to the COVID-19 pandemic. These forward-wanting statements are dependent on our existing expectations and beliefs and are issue to a range of dangers and uncertainties that could induce precise outcomes to vary materially from all those described in the ahead-wanting statements. This kind of challenges and uncertainties include, but are not constrained to, challenges associated with the Company’s enhancement function, like any delays or changes to the timing, value and success of our merchandise enhancement routines and medical trials and options chance of delays in Fda acceptance of Libervant and our other drug candidates or failure to receive acceptance chance of our capacity to reveal to the Fda “clinical superiority” inside the indicating of the Fda rules of our drug applicant Libervant relative to Food and drug administration-approved diazepam rectal gel and nasal spray solutions including by establishing a key contribution to affected individual treatment in the this means of Food and drug administration restrictions relative to the approved items as properly as threats similar to other potential pathways or positions which are or could in the future be advanced to the Food and drug administration to defeat the seven calendar year orphan drug exclusivity granted by the Food and drug administration for the approved nasal spray product of a competitor in the U.S. and there can be no assurance that we will be profitable risk that a competitor obtains Fda orphan drug exclusivity for a item with the exact same active moiety as any of our other drug goods for which we are seeking Food and drug administration approval and that such previously authorized competitor orphan drug blocks such other products candidates in the U.S. for seven yrs for the exact indicator risk inherent in commercializing a new product or service (like technology risks, money hazards, marketplace dangers and implementation pitfalls and regulatory constraints) threats for consummating the monetization transaction for KYNMOBI and other pitfalls and uncertainties concerning the royalty and other profits stream of KYNMOBI, accomplishment of royalty targets worldwide or in any jurisdiction and specific other business targets essential for contingent payments beneath the monetization transaction, and of sufficiency of net proceeds of the monetization transaction after fulfillment of and compliance with 12.5% Senior Notes obligations, as relevant, and for funding the Company’s functions hazard of development of our gross sales and marketing abilities chance of legal prices linked with and the result of our patent litigation demanding third bash at hazard generic sale of our proprietary items danger of sufficient cash and cash assets, together with access to available financial debt and equity funding and revenues from functions, to satisfy all of our shorter-expression and for a longer period expression cash specifications and other funds requirements, at the times and in the quantities needed possibility of failure to satisfy all financial and other financial debt covenants and of any default possibility linked to government promises towards Indivior for which we license, manufacture and offer Suboxone® and which accounts for the sizeable section of our present operating revenues chance related with Indivior’s cessation of creation of its approved generic buprenorphine naloxone movie product, including the affect from decline of orders for the authorized generic product and hazard of eroding market place share for Suboxone and chance of sunsetting product dangers associated to the outsourcing of particular promoting and other operational and team functions to 3rd functions risk of the charge and diploma of marketplace acceptance of our item and product candidates the results of any competing items, which includes generics hazard of the dimensions and development of our item markets hazards of compliance with all Fda and other governmental and client requirements for our production facilities risks linked with intellectual property rights and infringement statements relating to the Company’s products danger of sudden patent developments the impression of current and future laws and regulatory provisions on solution exclusivity laws or regulatory steps impacting pharmaceutical product pricing, reimbursement or obtain promises and challenges that could crop up about the security or efficacy of the Company’s merchandise and merchandise candidates risk of reduction of important prospects pitfalls associated to lawful proceedings, like patent infringement, investigative and antitrust litigation issues modifications in government regulations and laws danger of solution recollects and withdrawals uncertainties connected to standard economic, political, enterprise, sector, regulatory and current market disorders and other unconventional merchandise and other uncertainties affecting the Company explained in the “Risk Factors” part and in other sections incorporated in our Annual Report on Variety 10 K, in our Quarterly Studies on Variety 10-Q, and in our Present-day Stories on Type 8-K submitted with the Securities Exchange Fee (SEC). Specified people uncertainties, you should really not position undue reliance on these forward-on the lookout statements, which speak only as of the date built. All subsequent forward-seeking statements attributable to us or any man or woman acting on our behalf are expressly experienced in their entirety by this cautionary statement. The Corporation assumes no obligation to update ahead-searching statements or outlook or assistance immediately after the date of this press release no matter whether as a consequence of new info, long term occasions or normally, other than as could be essential by relevant regulation.

PharmFilm®, Sympazan® and the Aquestive logo are registered emblems of Aquestive Therapeutics, Inc. All other registered emblems referenced herein are the house of their respective proprietors.

Investor Inquiries:

Westwicke, an ICR Corporation
Stephanie Carrington
[email protected]
646-277-1282